SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines

Abstract

Since the emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019, when its characteristics were practically unknown, one aspect was evident: its high contagion rate. This high infection rate resulted in the spread of the virus in China, Europe, and, eventually, the rest of the world, including Mexico. At present, around 9 million people are infected, and around 470,000 have died worldwide. In this context, the need to generate protective immunity, and especially the generation of a vaccine that can protect the world population against infection in the shortest possible time, is a challenge that is being addressed in different countries using different strategies in multiple clinical trials. This opinion article will present the evidence of the induction of immune response in some of the viruses of the coronavirus family before COVID-19, such as SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus). The information collected about the induction of an immune response by SARS-CoV-2 will be presented, as well as a description of the vaccine candidates reported to date in the various ongoing clinical trials. Finally, an opinion based on the evidence presented will be issued on the potential success of developing vaccine prototypes.

Keywords: Ad5-nCoV vaccine; Bacillus Calmette-Guerin; Bacilo de Calmette-Guérin; COVID-19 vaccine; Coronavirus de Wuhan; SARS-CoV-2 vaccine; Vacuna Ad5-nCoV; Vacuna COVID-19; Vacuna SARS-CoV-2; Vacuna mRNA-1273; Wuhan coronavirus; mRNA 1273 vaccine.